Our Services
Medical Information
Helpful Resources
Published on: 6/14/2026
Immunotherapy can cause immune-related adverse events (irAEs) affecting the gastrointestinal tract (colitis), lungs (pneumonitis), endocrine glands (thyroiditis, adrenal insufficiency), liver (hepatitis), and heart (myocarditis). Oncologists monitor these side effects through:
Early detection is critical, since irAEs can escalate quickly if left unmanaged.
Worried about a new symptom during immunotherapy? Don't wait for your next appointment to wonder if something is wrong. Subtle changes—like fatigue, shortness of breath, diarrhea, or a racing heart—can be early signals of a treatable irAE, and time matters. Take a free, instant, online symptom check to better understand what's going on and confidently navigate your next steps with your care team.
Reviewed for medical accuracy: 06/14/2026
Immunotherapy has transformed cancer treatment by empowering the body's own immune system to attack tumor cells. While many patients experience significant benefits, these powerful drugs can also trigger immune-related side effects. Oncologists balance the promise of immunotherapy with careful monitoring to catch and manage side effects early. Understanding what they watch most closely can help you stay informed and speak up if something doesn't feel right.
Immunotherapy side effects—often called immune-related adverse events (irAEs)—occur when the activated immune system mistakenly attacks healthy tissues. These can range from mild to severe and affect different organs:
Skin
Gastrointestinal (GI)
Endocrine (Hormone)
Pulmonary (Lungs)
Hepatic (Liver)
Cardiac (Heart)
Renal (Kidneys)
Most side effects appear within weeks to a few months after starting therapy but can happen later. Early detection and treatment often allow patients to continue immunotherapy safely.
Oncologists use a combination of lab tests, imaging, and direct patient feedback to spot irAEs early:
Before starting immunotherapy, your team will establish baseline values. Regular blood work then tracks changes over time:
Complete Blood Count (CBC)
Monitors white blood cells, red blood cells, platelets.
Comprehensive Metabolic Panel (CMP)
Checks liver enzymes (ALT, AST), bilirubin, kidney function (creatinine, BUN), electrolytes.
Thyroid Function Tests
TSH, free T4 to catch hypo- or hyperthyroidism.
Adrenal Hormone Levels
Cortisol to detect adrenal insufficiency if symptoms suggest it.
Blood Glucose
For new-onset diabetes.
Periodic scans help detect organ-specific inflammation before symptoms become severe:
Chest CT Scan
Identifies pneumonitis early, even if breathing changes are subtle.
Abdominal Imaging
Ultrasound or CT may be used if liver enzyme elevations or abdominal pain arise.
At each visit, your oncologist or nurse will ask about new symptoms and do targeted exams:
Skin Examination
Look for new rashes, dryness, pigmentation changes.
Abdominal Palpation
Assess tenderness that might suggest colitis.
Lung Auscultation
Listen for crackles or wheezing hinting at pneumonitis.
Vital Signs
Blood pressure, heart rate, temperature to detect fevers or irregularities.
Your firsthand reports are critical. Oncologists encourage patients to track and share:
Keeping a daily symptom diary or phone app log helps your care team spot patterns.
While all organ systems are important, certain side effects can escalate rapidly. Oncologists pay particular attention to:
GI Toxicity (Colitis)
Pulmonary Toxicity (Pneumonitis)
Endocrine Dysfunction
Hepatic Injury (Hepatitis)
Cardiac Inflammation (Myocarditis)
Inform your care team right away if you experience:
Remember, prompt reporting can prevent complications and often allows you to continue therapy after proper management.
When irAEs arise, oncologists tailor treatment by severity:
Grade 1 (Mild)
Symptom monitoring; continue therapy.
Grade 2 (Moderate)
Hold immunotherapy; start low-dose corticosteroids (e.g., prednisone 0.5–1 mg/kg).
Grade 3–4 (Severe to Life-Threatening)
Permanent discontinuation or long steroid taper; may involve hospital admission and specialist consultations.
Additional supportive measures include topical creams for skin, anti-diarrheals for mild colitis, hormone replacement for endocrine issues, and oxygen or inhalers for pneumonitis.
If you experience any of the following, call 911 or go to the nearest emergency department:
For non-emergencies, always loop in your oncology team first. Timely intervention is key.
Immunotherapy offers hope to many cancer patients but demands attentive monitoring for immune-related side effects. Your oncologist uses a combination of lab tests, imaging, physical exams, and your own reports to catch irAEs early. By staying informed, keeping a clear symptom diary, and reporting new issues promptly, you play an essential role in your treatment's success.
If you notice any concerning changes in your health, try using a Medically approved LLM Symptom Checker Chat Bot to document what you're experiencing, then reach out to your doctor immediately about anything that could be life threatening or serious. Your care team is your strongest ally in managing side effects and keeping you on track for the best possible outcome.
(References)
* Haanen JBAG, Carbonnel F, Robert C, et al. ASCO Clinical Practice Guideline for the Management of Immune Checkpoint Inhibitor-Related Toxicities. J Clin Oncol. 2022 Oct 20;40(30):3454-3484. doi: 10.1200/JCO.22.01633. Epub 2022 Sep 27. PMID: 36166723.
* Pardoll DM, Chen L. Immune checkpoint inhibitor-related adverse events: diagnosis and management. Nat Rev Clin Oncol. 2020 Aug;17(8):465-481. doi: 10.1038/s41571-020-0382-y. Epub 2020 Jun 8. PMID: 32514032.
* Barlesi F, Vansteenkiste J, Adachi Y, et al. Management of Immune-Related Adverse Events: A Practical Guide. Front Oncol. 2021 May 28;11:666981. doi: 10.3389/fonc.2021.666981. PMID: 34123985; PMCID: PMC8194474.
* D'Amico MA, Zandman-Goddard G, Meriwether M. Immune checkpoint inhibitor-associated adverse events: A review for the general internist. Am J Med. 2020 Dec;133(12):1378-1386. doi: 10.1016/j.amjmed.2020.07.019. Epub 2020 Jul 29. PMID: 32735160.
* Champiat S, Roberti MP, Mussat A, et al. Monitoring and Management of Immune Checkpoint Inhibitor-Related Adverse Events in Clinical Practice. Curr Treat Options Oncol. 2020 Aug 17;21(9):74. doi: 10.1007/s11912-020-00918-z. PMID: 32808092; PMCID: PMC7432864.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.